| Typicality: | 0.343 |
| Saliency: | 0.219 |
| with the us department of defense | 6 | other |
| further | 3 | manner |
| between dr. david heckerman | 2 | other |
| vaccine → be developed in → collaboration | 7 |
| vaccine → be developed in → partnership | 5 |
| vaccine → be developed through → partnership | 3 |
| negative | neutral | positive |
| 0.017 | 0.748 | 0.235 |
| Raw frequency | 15 |
| Normalized frequency | 0.219 |
| Modifier score | 0.500 |
| Perplexity | 140.404 |